We are delighted to have supported Omni Partners LLP (Omni), the lower mid-market focused investment manager, with their acquisition of Aesthetic Technology Ltd (ATL). The acquisition and investment from Omni will accelerate ATL’s international expansion and product development into further medical treatment pathways.

Founded in 2012, ATL is a multi-award-winning LED phototherapy company specialising in the development of innovative energy-based devices for the medical, aesthetic and cosmetic markets. ATL is the manufacturer of Dermalux LED systems, a unique breakthrough technology that delivers advanced treatment of skin conditions through the optimisation of three clinically proven combined wavelengths. Medically CE certified for acne, wound healing, pain relief and the only LED system in the world to hold medical approval for psoriasis, Dermalux has been voted ‘Treatment of The Year’ for five consecutive years at the prestigious UK Aesthetic Awards.

The business is run by its experienced founding team, and Omni’s investment will facilitate their ambitious growth plans.

Being acquired by Omni is a very proud day for me and everyone at ATL, and recognition of everything we have achieved since we launched Dermalux just over ten years ago. Omni has a fantastic track record, and that coupled with their investment will accelerate our growth, with exciting developments being announced over the next couple of months. Omni definitely shares our vision for the company and our goal to build on the success we have enjoyed to date. Having celebrated ATL’s tenth anniversary just last month, I can’t wait to see what the next ten years will bring

Louise Taylor, Co-Founder of Aesthetic Technology Ltd

Charles Gallagher-Powell, Head of Private Equity at Omni says: “Aesthetic Technologies Ltd has been at the forefront of medical device technologies in the UK since 2012. We are proud to support the growth of this pioneering British business creating proprietary, ground-breaking products that signify quality, efficacy and safety. With significant tailwinds across the broader medical technology market, we look forward to working closely with ATL’s management and supporting their global expansion.”

Funding support for the deal was provided by leading alternative finance provider ThinCats. The deal team was led by Dave Sherrington, Head of Private Equity and Michell Heptinstall, Director Sponsors who commented: “We are delighted to have worked with the expert teams at Omni and ATL on this transaction and are excited to support the business through its next phase of growth.” Dave Sherrington added; “It’s gratifying that we can support investment into a business that is innovating in the medical technology space and this deal further signifies our commitment to supporting the private equity community.”

Both Omni’s Founder, Steven Clark, and Head of Private Equity, Charles Gallagher-Powell, who has prior experience working with aesthetic technology company Lumenis, will join the ATL board of directors.

Omni was advised by RSM UK Group LLP (Financial & Tax), Candesic Limited (Commercial), Mayer Brown LLP (Legal) and Gallagher UK (Insurance). ATL was advised by KPMG and Brabners LLP.